Table 2.
Clinical and pathologic characteristics of patients who received adjuvant chemotherapy and patients who did not receive adjuvant chemotherapy.
| Characteristic | No adjuvant chemotherapy (n = 51) | Adjuvant chemotherapy (n = 52) | P Value |
|---|---|---|---|
| Age at surgery, mean (SD), y | 68.7 (12.9) | 61.5 (10.5) | .004 |
| FIGO grade, no. (%) | .06 | ||
| 1 | 11 (21.6) | 4 (7.7) | |
| 2 | 17 (33.3) | 14 (26.9) | |
| 3 | 23 (45.1) | 34 (65.4) | |
| Histology, no. (%) | .009 | ||
| Endometrioid | 12 (23.5) | 25 (48.1) | |
| Nonendometrioid | 39 (76.5) | 27 (51.9) | |
| Lymphovascular space invasion, no. (%) | 23 (45.1) | 24 (46.2) | .91 |
| Myometrial invasion >50%, no. (%) | 32 (62.7) | 34 (65.4) | .78 |
| Primary tumor diameter >2 cm, no. (%) | 46/50 (92.0) | 50/51 (98.0) | .16 |
| Cervical stromal invasion, no. (%) | 8 (15.7) | 12 (23.1) | .34 |
| Stage, no. (%)a | .002 | ||
| IIICo | 33 (64.7) | 18 (34.6) | |
| IIICab | 18 (35.3) | 34 (65.4) | |
| Site of node positivity, no. (%) | .14 | ||
| Pelvis only | 29 (56.9) | 22 (42.3) | |
| Paraaortic ± pelvis | 22 (43.1) | 30 (57.7) | |
| Positivity in ≥3 nodes, no. (%) | 22 (43.1) | 25/51 (49.0) | .55 |
| Positive lymph node ratio >0.10, no. (%) | 17 (33.3) | 21/51 (41.2) | .41 |
| Extent of lymphadenectomy, no. (%)b | .03 | ||
| Anything less than systematic | 12 (23.5) | 4 (7.7) | |
| Systematic | 39 (76.5) | 48 (92.3) | |
| Adjuvant EBRT, no. (%) | 29 (58.0) | 28 (53.8) | .67 |
Abbreviations: EBRT, external beam radiotherapy; FIGO, International Federation of Gynecology and Obstetrics.
a
Stage: IIICo, positive node(s) only; IIICab, positive node(s) and adnexal involvement, uterine serosal involvement, vaginal involvement, and/or positive peritoneal cytology.
b
Systematic was defined as ≥10 pelvic and ≥5 paraaortic lymph nodes removed and histologically assessed.